BRIEF published on 01/27/2026 at 18:05, 11 days 12 hours ago Theranexus Liquidity Contract Half-Year Review Liquidity Contract PORTZAMPARC Financial Report Theranexus THX Pharma Actions
BRIEF published on 01/20/2026 at 18:05, 18 days 12 hours ago THX Pharma unveils its 2026 financial calendar Euronext Paris Financial Agenda Biopharmaceutical 2026 THX Pharma
BRIEF published on 01/20/2026 at 18:05, 18 days 12 hours ago THX Pharma Reveals 2026 Financial Schedule Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 18 days 12 hours ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 30 days 12 hours ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 30 days 12 hours ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
PRESS RELEASE published on 01/08/2026 at 18:00, 30 days 12 hours ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 1 month ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
BRIEF published on 01/07/2026 at 08:05, 1 month ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
PRESS RELEASE published on 01/07/2026 at 08:00, 1 month ago THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
Published on 02/07/2026 at 01:00, 1 day 5 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 7 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 8 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 15 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 17 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 9 hours 42 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 14 hours 6 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 14 hours 21 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 11 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 12 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 12 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 14 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 12 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
